
    
      This Phase 2b, multicenter, randomized, placebo-controlled study will evaluate the safety,
      tolerability, and immunogenicity of a respiratory syncytial virus stabilized prefusion F
      subunit vaccine (RSV vaccine) in pregnant participants who receive either one of 2 dose
      levels of the vaccine, formulated with or without aluminum hydroxide, or placebo, as well as
      assess safety and characteristics of transplacentally transferred antibodies in their
      infants.
    
  